Reports Q4 revenue $6.54M, consensus $3.26M .Cash, cash equivalents, and marketable securities as of December 31, 2022, were $437.4M, compared to $478.5M as of September 30, 2022, and $619.9M as of December 31, 2021. The company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
- Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
- Editas Medicine initiated with an Overweight at Cantor Fitzgerald
- Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
- Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech